November 19, 2003

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com



FOR IMMEDIATE RELEASE

ZOLL Unveils New EMS Products at MEDICA 2003

Wednesday, November 19, 2003 – Düsseldorf, Germany—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, unveils two new Emergency Medical Services (EMS) products. They are a Bluetooth® wireless technology option for ZOLL M Series Defibrillators and the ResQPOD™ Circulatory Enhancer for Cardiac Arrest from Advanced Circulatory Systems, Inc. These products—along with the ZOLL AED Plus™ with CPR Feedback—are on display at Stand E59 in Hall 11 during MEDICA 2003 from 19 November through 22 November.

The Bluetooth wireless option for the M Series offers both real-time digital transmission of 12-lead electrocardiogram (ECG) and vital signs information. The ResQPOD Circulatory Enhancer for Cardiac Arrest significantly increases blood flow to the heart and brain during CPR. Additionally, the ZOLL AED Plus automated external defibrillator with CPR Feedback helps rescuers by guiding them through the entire resuscitation process as defined by the American Heart Association (AHA) and the European Resuscitation Council (ERC).

“These products demonstrate ZOLL’s commitment to broaden our offerings beyond traditional defibrillation and pacing equipment,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “The ResQPOD enables EMS personnel to improve patient care in the field. The Bluetooth wireless option accelerates the transfer of vital patient data, which helps physicians make faster life-saving decisions and improve triage when patients arrive at the hospital.”

Below is an overview of each product on display at MEDICA 2003.

Bluetooth Wireless Option for M Series
The Bluetooth wireless option allows EMS personnel to digitally transmit 12-lead ECG and vital trend data with the simple push of a button. With this option, the M Series can send patient data wirelessly to a Bluetooth-enabled Pocket PC or Windows®-based laptop. The data is then sent via a data-enabled cellular phone to multiple locations.

Vital signs are automatically transmitted every minute so physicians have a complete record of a patient’s vital signs. Other benefits include:

· Faster transmission times, leading to lower costs. The Bluetooth wireless option provides faster transmission rates, when compared to Analog communications technologies, reducing the time needed to send patient information from the field. The 12-lead ECG and vital trend data are delivered in a matter of seconds, not minutes. The result is lower airtime charges as compared to traditional transmission methods.

· Integration with standard communications technologies. The Bluetooth wireless option works with a variety of existing Bluetooth-enabled Pocket PCs and cell phones. This allows customers to select the most appropriate technology for their service today, while ensuring that they can adapt to future changes in cellular technology.

The Bluetooth wireless option is now available to new and existing M Series customers. Contact ZOLL or an authorized distributor for information on a customized configuration and additional requirements.

ResQPOD Circulatory Enhancer for Cardiac Arrest
The ResQPOD Circulatory Enhancer for Cardiac Arrest increases blood flow to the body’s vital organs by creating a vacuum within the victim’s chest during the decompression phase of CPR. Its patented approach enhances CPR efficiency by utilizing the interdependence of the body’s respiratory and circulatory systems. With it, up to two times as much blood is circulated to the heart and brain when compared to CPR without the ResQPOD. Benefits include:

· Demonstrated clinical results. A combination of animal and human studies show statistically significant levels of improvement in survival from cardiac arrest and normal neurological function when the ResQPOD is used in conjunction with standard CPR.

· Easy integration into a rescue routine. The ResQPOD works in combination with standard resuscitation techniques, including standard or pump-assisted CPR.

The ResQPOD is CE approved for sale in Canada and Europe.

AED Plus with CPR Feedback
The AED Plus is the only AED that helps rescuers achieve the recommended depth and rate of chest compressions during CPR. By creating a device that focuses on every step of the rescue process, ZOLL differentiates its AED from other products. While other AEDs concentrate on the delivery of the “shock,” ZOLL’s AED Plus guides rescuers through the AHA/ERC’s “Chain of Survival,” including checking the victim’s vital signs, calling 911, defibrillation, and the proper administration of CPR.

The AED Plus with CPR Feedback has a unique one-piece pre-connected electrode, known as the CPR-D•padz™. It applies easily to a patient’s chest and fits 99 percent of patients; a slight adaptation allows it to fit the other 1 percent. Its patented technology offers an unmatched four-year shelf life, twice that of others on the market. The CPR-D•padz includes a hand-placement locator and accurately measures CPR compressions, allowing for feedback on proper rate and depth. Audio feedback tells a rescuer, “Press Harder” or “Good Compressions.”

The AED Plus is the only device to use cost-effective off-the-shelf lithium batteries. It is immediately recognized by its distinct lime-green color, which was chosen for its association with safety, calming effect on the rescuer, and its ability to be easily seen.

About ZOLL
ZOLL Medical Corporation (NASDAQ: ZOLL), with worldwide headquarters in Chelmsford, Massachusetts, designs, manufactures, and markets resuscitation solutions. Pacing and defibrillation devices, including ZOLL’s M Series and AED Plus, and LIFECOR, Inc.’s LifeVest™ Wearable Defibrillator; and circulatory assist devices such as Advanced Circulatory Systems, Inc.’s ResQPOD™ Circulatory Enhancer and Revivant Corporation’s AutoPulse™; are used by health care professionals, emergency medical service providers, and first responders to diagnose and treat cardiac arrest wherever it may occur. ZOLL also designs and markets software that automates the collection and management of both clinical and non-clinical data. ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, the Netherlands, and Australia, and business partners in all of the world’s major markets. For more information about ZOLL, its products and partners, visit www.zoll.com or call 978-421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the anticipated growth in the hospital market, our ability to grow AED sales and increase AED market share, our outlook for the Company, our anticipated sales and earnings growth, our beliefs regarding the North American market, our ability to successfully build our AED business and our ability to grow our International sales, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 13, 2003, including the future performance of the direct sales operations, as well as uncertainties regarding the market acceptance and profitability of the ZOLL AED Plus, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the impact of governmental budget restraints on the purchase of capital equipment, the continued war in the Middle East, the impact of the war on terrorism, the potential disruption in the transportation industry on the Company’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the Company's products.

# # #

Copyright © 2003 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105.
All trademarks are property of their respective owners.